Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Sep
08
Today In Oncology
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Duane Mitchell Named Director of the UF Health Cancer Institute
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo